Natixis’s IDEAYA Biosciences IDYA Stock Holding History

Natixis’s Portfolio IDYA Stock Details IDYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200,000	Closed	-$4.73M	–	1238
2021 Q4	$4.73M	Buy	+200,000	New	+$4.65M	0.02%	564

Other funds holding IDYA

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Natixis's IDYA Position: Q1 2022 in Review

Natixis sold out of IDEAYA Biosciences (IDYA) in Q1 2022, closing a stake of 200,000 shares — an estimated $4.73M sold.

Natixis first reported a position in IDYA in Q4 2021 and held it in 1 quarter. The position peaked at $4.73M in Q4 2021. 103 funds tracked by Wall St. Rank hold IDYA as of Q1 2022.

Natixis reported no remaining IDEAYA Biosciences position as of Q1 2022 after selling out during the quarter.
Natixis sold 200,000 IDEAYA Biosciences shares in Q1 2022, an estimated $4.73M.
Natixis first reported a position in IDEAYA Biosciences in Q4 2021 and held it in 1 quarter.
Natixis's IDEAYA Biosciences position peaked at $4.73M in Q4 2021.
103 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q1 2022.

Based on Natixis's 13F filing for Q1 2022, filed 13 May 2022.